Structure–Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist-Reference-Cited by-同舟云学术

Structure–Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist

Published:2017-11-20 Issue:23 Volume:60 Page:9641-9652
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Di Maro Salvatore¹,Di Leva Francesco Saverio²,Trotta Anna Maria³,Brancaccio Diego²,Portella Luigi³,Aurilio Michela⁴,Tomassi Stefano¹,Messere Anna¹,Sementa Deborah²,Lastoria Secondo⁴,Carotenuto Alfonso²,Novellino Ettore²^ORCID,Scala Stefania³,Marinelli Luciana²^ORCID

Affiliation:

1. DiSTABiF, University of Campania “Luigi Vanvitelli”, Caserta 81100, Italy

2. Department of Pharmacy, University of Naples “Federico II”, Via D. Montesano 49, 80131 Naples, Italy

3. Functional Genomics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Via M. Semmola 52, 80131 Naples, Italy

4. Nuclear Medicine Unit, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Via M. Semmola 52, 80131 Naples, Italy

Funder

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01062

Reference76 articles.

1. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells

2. The Intricate Role of CXCR4 in Cancer

3. Pre-metastatic niches: organ-specific homes for metastases

4. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving strategies and application of proteins and peptide therapeutics in cancer treatment;Biomedicine & Pharmacotherapy;2023-07

2. Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications;Journal of Medicinal Chemistry;2023-06-16

3. Utilization of macrocyclic peptides to target protein-protein interactions in cancer;Frontiers in Oncology;2022-11-17

4. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections;Journal of Controlled Release;2022-08

5. Chemo-Selective Cys–Pen Disulfide for Proximity-Induced Cysteine Cross-Linking;ACS Chemical Biology;2022-02-28